Fu Shuliang Instructions

Many people don’t really know what Fushunliang is. Fushunliang is mainly used to prevent and effectively treat infections, seasonal allergies, rhinitis, and nasal membrane inflammation diseases. However, everyone needs to pay attention that the use of Fushunliang is not very simple. During the use process, it is necessary to adjust it according to the development of the individual’s physical condition.

Fluticasone propionate. The concentration of the drug solution is 0.05%, which is equivalent to 50 micrograms of fluticasone propionate per spray. The excipients are: glucose, microcrystalline cellulose and sodium carboxymethyl cellulose, phenylethyl alcohol, benzalkonium chloride, Tween 80, dilute hydrochloric acid, and pure water.

Indications : Prevention and treatment of seasonal allergic rhinitis (including hay fever) and perennial rhinitis. It has potent anti-inflammatory activity, but no systemic activity has been detected when applied topically to the nasal mucosa. The main ingredient is fluticasone propionate. The concentration of the drug solution is 0.05%, which is equivalent to 50 micrograms of fluticasone propionate per spray. The excipients are: glucose, microcrystalline cellulose and sodium carboxymethyl cellulose, phenylethyl alcohol, benzalkonium chloride, Tween 80, dilute hydrochloric acid, and pure water.

Description of properties: This product is fluticasone propionate nasal spray (0.05% w/w), which is a white suspension of micronized fluticasone propionate particles. Pharmacology Fluticasone propionate has potent anti-inflammatory activity but has little systemic activity when administered topically to the nasal mucosa. Fluticasone propionate has minimal inhibitory potential on the hypothalamic-pituitary-adrenal axis when administered nasally or topically (transdermally) at therapeutic doses. Only at very high oral doses (10 mg four times a day: ie 40 mg per day or more) does a significant inhibitory effect occur. Toxicology Toxicology studies have shown that typical effects of a potent corticosteroid occur only at doses significantly exceeding the intended therapeutic dose. Fluticasone propionate was not mutagenic in the Ames test, the Escherichia coli reverse mutation test, the S. cerevisiae gene mutation test, or the Chinese hamster ovary cell test. It was not clastogenic in the mouse micronucleus cell assay and the cultured human lymphocyte assay. In completed studies on fertility and general reproductive function in rats, subcutaneous administration of fluticasone propionate at 50 μg/kg/day in females and 100 μg/kg/day in males (subsequently reduced to 50 μg/kg/day) did not affect mating and fertility. Animal studies evaluating the effects of fluticasone propionate on embryonic development in mice, rats, and rabbits have been completed. Subcutaneous administration of fluticasone propionate to pregnant mice resulted in effects typical of this class of drugs. A toxic dose of 150 μg/kg in maternal rats resulted in a decrease in maternal body weight and, as expected, induced cleft palate in some fetuses. Weight loss, fetal growth retardation, delayed ossification and a small amount of omphalocele in rats all prove that a dose of 100 μg/kg can cause miscarriage, a dose of 0.57 μg/kg-4.0 μg/kg can cause fetal weight loss, and a high dose can cause cleft palate. However, oral doses of 300 μg/kg were not maternally or embryonally toxic. In a fertility study in rats, a dose of 50 μg/kg affected maternal body weight and dose-dependently affected F0 and F1, but had no significant effect on prenatal and postnatal growth and development of rats. There are no adequate well-controlled studies in pregnant women. It is not known whether nasal fluticasone propionate passes into breast milk. Small amounts of systemically administered glucocorticoids are secreted in breast milk.

In the drug efficacy experiment, the plasma concentration of fluticasone propionate was still very low when the nasal dose was as high as 1 mg, close to the quantitative analysis limit of 0.05 ng/ml. Following oral administration of fluticasone propionate, 87-100% of the dose is excreted in the feces, of which 75% is unchanged drug. After oral administration of 46 mg, 64% was excreted as unchanged substance, producing an inactive major metabolite. After intravenous administration, it is rapidly cleared from plasma, suggesting extensive hepatic uptake. Based on limited data, a plasma elimination half-life of 3 hours has been determined and an apparent volume of distribution greater than three times body weight, suggesting extensive tissue distribution and rapid clearance. Contraindications: Patients who are allergic to any of the ingredients in the fluticasone propionate water-soluble nasal spray are contraindicated. It is contraindicated for those who are allergic to any ingredient in this product. Precautions: Nasal infections should be treated appropriately, but this is not a contraindication for the use of this drug. It takes several days for Fushuliang to produce the maximum therapeutic effect. In the presence of adrenal impairment, caution must be exercised when switching from systemic corticosteroids to fluticasone propionate aqueous nasal spray. Pregnancy and lactation When fluticasone propionate is used by pregnant or lactating women, the benefits of the drug should be weighed against the potential harm to the mother and baby. Side effects: Nasal septum perforation has been reported after intranasal corticosteroids, but it is extremely rare and usually occurs in patients who have undergone nasal surgery. Like other nasal inhalers, this product can cause dryness and irritation of the nose and throat, unpleasant taste and odor, and epistaxis and headache have been reported. As with other nasal sprays, systemic effects may occur, especially when used in high doses and for long periods of time

<<: Meropenem instructions

>>: Thymopentin Instructions